Compare ELBM & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELBM | PMVP |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.9M | 66.1M |
| IPO Year | 2022 | 2020 |
| Metric | ELBM | PMVP |
|---|---|---|
| Price | $0.51 | $1.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.15 | N/A |
| AVG Volume (30 Days) | ★ 302.6K | 300.8K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $1.02 |
| 52 Week High | $8.70 | $1.88 |
| Indicator | ELBM | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 38.21 |
| Support Level | $0.50 | $1.07 |
| Resistance Level | $0.60 | $1.26 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 7.67 | 0.71 |
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry. The Company's operating segments are Refinery, Exploration and Evaluation, Corporate and Other.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.